A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer
Status:
Completed
Trial end date:
2021-03-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine
in participants with platinum-sensitive, extensive-stage small-cell lung cancer.